Added to YB: 2026-08-04
Pitch date: 2026-07-31
IVA [bullish]
Inventiva S.A.
-1.3%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
Market Cap
EUR 897.9M
Pitch Price
EUR 3.84
Price Target
7.50 (+98%)
Dividend
N/A
EV/EBITDA
-7.91
P/E
-2.00
EV/Sales
152.18
Sector
Biotechnology
Category
special_situation
Can Inventiva crack the crowded MASH market? ($IVA)
IVA: Binary MASH biotech; lead pan-PPAR agonist lanifibranor with strong Ph2b data (hit SAF endpoint, MASH resolution, fibrosis regression). €233.9M cash funds tight runway to pivotal Ph3 NATiV3 readout Q4 2026. Bull: clean data re-rates + non-dilutive pharma deal. Bear: single-asset miss triggers €130M BlackRock default, wipeout to $0.50. PT $7.50 (+62%), high-side $12 vs $4.62.
Read full article (5 min)